François Guilhot
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 285
- Chronic Myeloid Leukemia Treatments 236
- Acute Myeloid Leukemia Research 47
- Multiple Myeloma Research and Treatments 14
- Genetics 226
- Chronic Lymphocytic Leukemia Research 213
- Myeloproliferative Neoplasms: Diagnosis and Treatment 23
- Co-authors
- Brian Druker (36 shared papers)Andreas Hochhaus (41 shared papers)Richard A. Larson (29 shared papers)Timothy P. Hughes (36 shared papers)Joëlle Guilhot (66 shared papers)Jerald P. Radich (13 shared papers)Stephen G. O’Brien (17 shared papers)Michele Baccarani (38 shared papers)
- Journals
- Blood (116 papers)Journal of Clinical Oncology (29 papers)Leukemia Research (13 papers)British Journal of Haematology (11 papers)Leukemia (11 papers)
- Partner nations
- FranceUnited StatesGermany
In The Last Decade
François Guilhot
342 papers receiving 18.0k citations
François Guilhot's Hit Papers
Peers
Comparison fields: 5 of 130
- Hematology 14.7k
- Genetics 10.6k
- Rheumatology 6.7k
- Oncology 3.4k
- Pathology and Forensic Medicine 1.8k
Countries citing papers authored by François Guilhot
This map shows the geographic impact of François Guilhot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by François Guilhot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites François Guilhot more than expected).
Fields of papers citing papers by François Guilhot
This network shows the impact of papers produced by François Guilhot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by François Guilhot. The network helps show where François Guilhot may publish in the future.
Co-authors
The 25 scholars most cited alongside François Guilhot, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 351 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia Hit paper breakdown → | 2002 | 1517 |
| 2 | Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Hit paper breakdown → | 2010 | 1046 |
| 3 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet Hit paper breakdown → | 2009 | 890 |
| 4 | Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Hit paper breakdown → | 2017 | 797 |
| 5 | Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma Hit paper breakdown → | 2003 | 699 |
| 6 | Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Hit paper breakdown → | 2009 | 627 |
| 7 | Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Hit paper breakdown → | 2008 | 491 |
| 8 | International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Hit paper breakdown → | 2009 | 444 |
| 9 | 2010 | 349 | |
| 10 | Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia Hit paper breakdown → | 2016 | 315 |
| 11 | 2006 | 301 | |
| 12 | 2011 | 290 | |
| 13 | An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. | 1999 | 286 |
| 14 | 2007 | 279 | |
| 15 | 2007 | 277 | |
| 16 | 1997 | 252 | |
| 17 | 2016 | 230 | |
| 18 | 2009 | 229 | |
| 19 | 2009 | 214 | |
| 20 | 2016 | 193 |
About François Guilhot
François Guilhot is a scholar working on Hematology, Genetics, Rheumatology, Public Health, Environmental and Occupational Health and Oncology, having authored 351 papers that have together received 18.5k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (236 papers), Chronic Lymphocytic Leukemia Research (213 papers), Eosinophilic Disorders and Syndromes (108 papers), Acute Lymphoblastic Leukemia research (58 papers), Acute Myeloid Leukemia Research (47 papers), Lymphoma Diagnosis and Treatment (37 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (23 papers) and Multiple Myeloma Research and Treatments (14 papers). The work is most often cited by research in Hematology (14.7k citations), Genetics (10.6k citations), Rheumatology (6.7k citations), Oncology (3.4k citations) and Pathology and Forensic Medicine (1.8k citations). François Guilhot has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Brian Druker, Andreas Hochhaus, Richard A. Larson, Timothy P. Hughes, Joëlle Guilhot, Jerald P. Radich, Stephen G. O’Brien, Michele Baccarani, Dietger Niederwieser and Jörge E. Cortes. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia Research, British Journal of Haematology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.